NIH, GreenLight Biosciences to collaborate on COVID-19 vaccine development for new variants
In addition, they will work together to develop systems that expedite new designs into clinical use.
- In addition, they will work together to develop systems that expedite new designs into clinical use.
- For the current COVID-19 pandemic and future coronavirus-related pandemics, the rapid development and deployment of vaccines active against a range of coronaviruses, including variants of SARS-CoV-2, will be vital for public health.
- Government scientists serve the larger mission of NIH, to facilitate the development and commercialization of health-care pharmaceuticals and products.
- GreenLight Biosciences aims to address some of the worlds biggest problems by delivering on the full potential of RNA for human health and agriculture.